Two commercial collaborations aim to expand high‑throughput functional genomics and epigenomics. Parse Biosciences struck a deal with Codebreaker Labs to combine engineered variant libraries with Parse’s single‑cell transcriptomics platform to experimentally map how genetic variants alter cell states; the program could inform target discovery and AI training datasets. Separately, Wasatch BioLabs and Agilent launched a co‑marketing push for a targeted nanopore methylation sequencing service developed jointly and offered under early‑access. Qiagen’s pending acquisition of Parse and the commercial roll‑out of nanopore methylation assays underscore accelerating industry demand for large, labeled single‑cell and epigenetic datasets.